Type 1 Diabetes Cured in Mice With 100% Success Rate, No Drugs Needed

Stanford University researchers have cured Type 1 diabetes in laboratory mice by creating a hybrid immune system that stops the body's attack on insulin-producing cells. The approach achieved a 100% cure rate without the need for lifelong immune-suppressing drugs, opening a realistic path to human clinical trials.

How It Works

In Type 1 diabetes, the immune system mistakenly destroys islet cells in the pancreas that produce insulin. Transplanting donor islet cells can help, but the recipient's immune system attacks them as foreign invaders, requiring lifelong immunosuppression with severe side effects.

The Stanford team, led by Seung K. Kim and Judith Shizuru, developed a gentler approach. They gave mice a combination of antibodies, low-dose radiation, and a rheumatoid arthritis drug called baricitinib to partially reset the immune system. They then transplanted both blood stem cells and islet cells from a donor, creating a hybrid (chimeric) immune system containing elements of both the recipient and the donor.

The result: the transplanted cells were not attacked. The immune system began functioning normally again. 19 out of 19 prediabetic mice were protected from developing diabetes. 9 out of 9 mice with established diabetes were cured. No animals required insulin or immunosuppressive drugs for the duration of the six-month study.

What Is a Chimeric Immune System?

A chimeric immune system contains immune cells from two different sources, the patient and the donor, coexisting in balance. The donor's immune cells teach the recipient's system to tolerate the transplanted tissue, while the recipient's cells continue protecting against infections. The term "chimera" comes from Greek mythology, referring to a creature made from parts of different animals.

The Path to Human Trials

The antibodies, drugs, and low-dose radiation used in the study are already part of standard clinical practice for blood stem cell transplantation. This makes translation to human trials a logical next step.

However, experts urge caution. Dr. John DiPersio, an oncologist at Washington University, noted that maintaining a balanced chimeric immune system over human decades is much harder than over a mouse's one-to-two-year lifespan. "It's a big step forward," he said, "but there are hurdles."

The study was published in the Journal of Clinical Investigation.